Annals of Tropical Medicine and Public Health
Home About us Ahead Of Print Instructions Submission Subscribe Advertise Contact e-Alerts Editorial Board Login 
Users Online:1656
  Print this page  Email this page Small font sizeDefault font sizeIncrease font size
ORIGINAL ARTICLE
Year : 2015  |  Volume : 8  |  Issue : 5  |  Page : 202-205

Prevalence of transfusion-transmitted infections in multiple blood transfused thalassemia patients: A report from a tertiary care center in North India


Department of Transfusion Medicine, Government Medical College, Jammu, Jammu and Kashmir, India

Correspondence Address:
Meena Sidhu
F-234, Raipur Satwari, Jammu Cantt, Jammu and Kashmir
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1755-6783.159849

Rights and Permissions

Aims: The present study was undertaken to estimate the prevalence of transfusion-transmitted infections (TTIs) in multitransfused patients of thalassemia major and to determine the association with relation to the number of blood units being transfused in Jammu province. Materials and Methods: The study was conducted on 138 beta thalassemia patients registered for regular blood transfusions at the Department of Blood Transfusion Medicine, Shri Maharaja Gulaab Singh Hospital, Government Medical College, Jammu in the period July-December 2014. The tests for TTIs, i.e., human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV), were performed by using third-generation enzyme-linked immunosorbent assay (ELISA) kits. Statistical Analysis: The data were analyzed as proportions. The statistical significance of the results was evaluated using the chi-squared test/Fisher's exact test. A P value of <0.05 was considered significant. Results : Out of 138 patients, 13.7% (19/138) were seroreactive for TTIs. Of these seroreactive patients, 13.04% (18/138) were positive for anti-HCV and 0.72% (1/138) positive for anti-HIV. Of the anti-HCV reactive cases, 66.66% were >15 years of age. Of the anti-HCV positive cases, 94.4% (17 out of 18) had received more than 100 transfusions. Anti-HCV seroreactivity was noted to increase with increase in the age of the patient and the number of transfusions. Conclusion: HCV is the main TTI in multitransfused thalassemic patients. HBV vaccination must be done before starting the transfusion regimen or as soon as otherwise possible.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2356    
    Printed61    
    Emailed1    
    PDF Downloaded22    
    Comments [Add]    

Recommend this journal